Edition:
United States

Mediwound Ltd (MDWD.OQ)

MDWD.OQ on NASDAQ Stock Exchange Global Market

4.70USD
14 Dec 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$4.70
Open
$4.75
Day's High
$4.75
Day's Low
$4.60
Volume
2,699
Avg. Vol
9,776
52-wk High
$8.25
52-wk Low
$4.20

Latest Key Developments (Source: Significant Developments)

MediWound Q3 loss per share $0.49
Thursday, 16 Nov 2017 07:00am EST 

Nov 16 (Reuters) - MediWound Ltd -:MediWound reports third quarter 2017 financial results.Q3 loss per share $0.49.Q3 revenue $740,000 versus I/B/E/S view $790,000.Q3 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S.MediWound - ‍expected cash use to support operating activities in 2017 will remain toward lower end of co's guidance range for 2017 of $15 million -$17 million​.MediWound Ltd - ‍company may bear an additional $1.5 million expense to purchase shares of PolyHeal pursuant to district court ruling in Q4 of 2017​.  Full Article

Tel Aviv district court ordered Mediwound to purchase about $1.5 mln of PolyHeal shares
Monday, 13 Nov 2017 09:32pm EST 

Nov 13 (Reuters) - Mediwound Ltd :Tel Aviv district court ordered Mediwound to purchase approximately $1.5 million of PolyHeal shares; Mediwound weighing an appeal.‍Continues to evaluate ruling and its legal and accounting implications and company's options, including a potential appeal​.Court ordered that co is obligated to purchases shares of 3 shareholders of PolyHeal pursuant to claim made by such PolyHeal shareholders​.  Full Article

MediWound appoints Mr. Stephen T. Wills as chairman
Wednesday, 25 Oct 2017 07:00am EDT 

Oct 25 (Reuters) - Mediwound Ltd :MediWound appoints Mr. Stephen T. Wills as chairman to its Board of Directors.Mediwound Ltd - ‍ appointment of Stephen T. Wills as chairman upon resignation of Aharon Yaari from Board​.Mediwound Ltd - ‍ Wills currently serves as Chief Financial Officer and Chief Operating Officer of Palatin Technologies​.  Full Article

MediWound Ltd announces new distribution agreement with Holy Stone Healthcare for NexoBrid
Monday, 16 Oct 2017 08:00am EDT 

Oct 16 (Reuters) - MediWound Ltd :MediWound Ltd - ‍ announced an agreement with Holy Stone Healthcare, co for distribution of Nexobrid in Taiwan for treatment of severe burns​.  Full Article

MediWound announces pricing of $22 million public offering of ordinary shares
Tuesday, 19 Sep 2017 06:30am EDT 

Sept 19 (Reuters) - Mediwound Ltd :MediWound announces pricing of $22 million public offering of ordinary shares.MediWound Ltd - ‍pricing of an underwritten public offering of 4.4 million of its ordinary shares at a price to public of $5.00 per share​.  Full Article

MediWound Ltd announces public offering of ordinary shares
Monday, 18 Sep 2017 04:07pm EDT 

Sept 18 (Reuters) - MediWound Ltd :MediWound Ltd. announces public offering of ordinary shares.MediWound Ltd - ‍Commenced an underwritten public offering of its ordinary shares​.MediWound Ltd - ‍All of ordinary shares are being offered by MediWound​.  Full Article

MediWound successfully completes second cohort of EscharEx phase 2 study
Friday, 1 Sep 2017 08:00am EDT 

Sept 1 (Reuters) - Mediwound Ltd :MediWound successfully completes second cohort of EscharEx phase 2 study.MediWound Ltd - ‍overall patient demographics and wound baseline characteristics were comparable across both arms in study​.MediWound - ‍related systemic adverse events were reported & adverse events related to local application were mild to moderate, reversible & resolved during trial​.MediWound Ltd - ‍intend to initiate EscharEx U.S. phase 3 pivotal program in first half of 2018​.  Full Article

Mediwound reports Q2 loss per share $0.20
Thursday, 3 Aug 2017 07:00am EDT 

Aug 3 (Reuters) - Mediwound Ltd :Mediwound reports second quarter 2017 financial results.Q2 loss per share $0.20.Q2 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S.Mediwound Ltd - ‍upsizes committed funding by additional $32 million, bringing total contract value to up to $132 million of non-dilutive financing​.Mediwound Ltd - ‍total revenues for Q2 of 2017 were $0.69 million, a 93% increase​.Q2 revenue view $737000.00 -- Thomson Reuters I/B/E/S.  Full Article

BARDA upsizes contract with MediWound and exercises option to fund further NexoBrid indications
Wednesday, 19 Jul 2017 04:15pm EDT 

July 19 (Reuters) - Mediwound Ltd :BARDA upsizes contract with MediWound and exercises option to fund further NexoBrid® indications.MediWound -BARDA increased its committed funds to support nexobrid research and development activities by $32 million to approximately $56 million, up from original $24 million.MediWound Ltd says BARDA maintains an additional option to further fund $10 million in development activities for other potential NexoBrid indications.MediWound Ltd says contract also maintains BARDA's $16 million commitment for procurement of NexoBrid.MediWound Ltd says total non-dilutive funding to MediWound under BARDA contract is now valued at up to $132 million.  Full Article

MediWound says received written Notice of Intent from BARDA
Friday, 23 Jun 2017 08:26am EDT 

June 23 (Reuters) - MediWound Ltd :Barda gives notice of intent to exercise first contract option to further fund mediwound’s nexobrid® development.Mediwound ltd - total non-dilutive funding to mediwound under barda contract is up to $112 million.  Full Article

BRIEF-MediWound Q3 loss per share $0.49

* Q3 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S